EIF2A and acute myeloid leukemia: Treatment with SB633825 in AML cell lines and samples results in minimal passive release of HMGB1, heightened exposure of CALR, and increased phosphorylation of eIF2α upon apoptosis induction at a half-lethal dose of SB633825.